Imaging - Science Track Award for Research Transition (I/START) (R03- Clinical Trial Optional)

The NIH's National Institute on Drug Abuse (NIDA) has reissued the *Imaging - Science Track Award for Research Transition (I/START)* (R03 Clinical Trial Optional), aimed at fostering the integration of brain imaging techniques, such as PET and MRI scans, into substance use and substance use disorder (SUD) research. This program is designed to facilitate the entry of both new and established investigators into neuroimaging research, enabling small, proof-of-concept studies that can produce preliminary data for larger, multi-year research grants. It offers an opportunity for researchers to explore neurobiological mechanisms underlying addiction, the cognitive and behavioral impacts of substance use, and the efficacy of SUD treatments. The inclusion of clinical trials is optional, though the study must demonstrate relevance to substance use or SUD. The program provides up to $150,000 in direct costs for a project lasting one year. These funds are intended to support focused projects that can be completed in a short time frame with limited resources. The research proposed should significantly contribute to understanding central nervous system (CNS) dysfunction related to substance use, as well as potential interventions, risk factors, and recovery mechanisms. Studies involving brain imaging and their application in SUD research can include various research areas, from addiction neurobiology and individual susceptibility to addiction, to recovery and treatment response. Researchers may also explore imaging-based biomarkers for SUD risks or resilience. Eligible applicants include higher education institutions (both public and private), non-profits, for-profit organizations, tribal organizations, and foreign institutions. Both U.S.-based and non-U.S. institutions are encouraged to apply, provided they meet NIH eligibility standards. The program does not require cost sharing, and applicants are permitted to submit multiple scientifically distinct applications. New submissions, as well as resubmissions of previous proposals, are accepted under this opportunity. The application process requires strict adherence to NIH submission guidelines, including the use of specific forms and formats as described in the SF424 (R&R) Application Guide. Applications can be submitted electronically via the NIH ASSIST system or through Grants.gov Workspace. All required institutional registrations, including those with eRA Commons and the System for Award Management (SAM), must be completed in advance of submission. It is critical that applicants ensure all documents are compliant, as non-conforming applications will not be reviewed. Review of applications will be based on standard NIH criteria, focusing on significance, investigator capability, innovation, approach, and environment. Special attention will be given to the potential of the proposed research to advance the field of substance use imaging research and generate data for future R01 or equivalent applications. Applications will undergo peer review, with feedback provided via the eRA Commons system. Deadlines follow NIH’s standard due dates, with submission dates spread across several cycles annually. For non-AIDS applications, the first deadline is October 16, 2024, with a rolling expiration date through January 8, 2028. Researchers are encouraged to contact NIDA program staff to discuss their project ideas before submission to ensure alignment with the program's goals.